The addition of elotuzumab (Empliciti) to pomalidomide (Pomalyst) and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma, according to findings from the phase II ELOQUENT-3 trial reported at the 2018 EHA Congress. Median progression-free survival (PFS) was 10.3 months (95%...Continue Reading
PHYSICAL ADDRESS
Floor 7, 90 The Terrace
Wellington Central
New Zealand